MANAGEMENT OF SUPERFICIAL THROMBOPHLEBITIS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。目的：验证布洛芬800mg每日口服3次，连用7天治疗浅表血栓性静脉炎的假设：就诊时皮下给药200单位/kg，随后再皮下给药10000单位1次，连用6天。具体目标目的：通过超声成像评估就诊时使用达尔特帕林200单位/kg，随后每日1次皮下注射10000单位（sc）或布洛芬800mg口服3次（每日1次）的患者的浅表性血栓性静脉炎扩展发生率。2. 评估在服用处方药物时疼痛的缓解程度。3. 评估与治疗相关的出血风险。4. 收集浅表性血栓性静脉炎患者的描述性/人口学数据。5. 对使用低分子肝素（Fragmin）与口服布洛芬治疗浅表性血栓性静脉炎进行药物经济学评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: Test the hypothesis that Fragmin (dalteparin sodium) 200 units/kg subcutaneously given at the time of presentation followed by 10,000 units given subcutaneously once daily for 6 days is more effective that Ibuprofen 800mg given orally three times daily for 7 days for the treatment of superficial thrombophlebitis. Specific Aims 1. To evaluate the incidence of extension of superficial thrombophlebitis by ultrasound imaging in patients treated with dalteparin 200 units/kg at presentation followed by 10,000 units subcutaneously (sc) once daily or Ibuprofen 800mg orally three times daily. 2. To evaluate the degree of pain resolution while taking the prescribed medication. 3. To evaluate the risk of bleeding associated with the treatments. 4. To gather descriptive/demographic data on patients with superficial thrombophlebitis. 5. To perform a pharmacoeconomic assessment of treatment of superficial thrombophlebitis using low molecular weight heparin (Fragmin) versus oral ibuprofen.